Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
Morning Overview on MSN
Pfizer settles patent fights, keeping heart drug shielded from generics to 2031
Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...
New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results